335. ALEMTUZUMAB FOR THE TREATMENT OF REFRACTORY BEHÇET’S DISEASE: A SUBGROUP ANALYSIS FROM A RANDOMIZED, PROSPECTIVE, OPEN LABEL, DOSE RANGING CLINICAL TRIAL (NCT01405807). A TRIAL OF EFFICACY AND SAFETY (ALEVIATE)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.